New drug shows promise for rare inflammatory disease
Disease control
Completed
This phase 2 trial tested the drug zanubrutinib in 10 people with IgG4-related disease, a condition that causes swelling in glands and other organs. The goal was to see if the drug could reduce gland size and inflammation over 24 weeks. Researchers measured changes using PET-MRI …
Phase: PHASE2 • Sponsor: Matthew C. Baker • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC